In silico– tag –
-
Google DeepMind’s AlphaFold 3 Achieves Unprecedented Accuracy in Predicting Molecular Interactions, Driving AI-Discovered Drugs to Phase III Trials
New Market Pitch Unknown Overview AI drug discovery is now fully functional in structural prediction, molecular design, lead optimization, and protein engineering. Google DeepMind and Isomorphic Labs' AlphaFold 3 demonstrates superior ac... -
Gamgee Leverages ChatGPT and AlphaFold to Design Personalized mRNA Cancer Vaccine for Dogs, Accelerating Clinical Trials with AI
Gies Business (Facebook) USA Overview AI is proving to be a catalyst for accelerating all facets of clinical trials, exemplified by Gamgee's use of ChatGPT and AlphaFold to design a personalized mRNA cancer vaccine for dogs, now in clini... -
UBC Bolsters AI-Driven Drug Discovery and Protein Design with New Research Chairs
UBC Medicine Canada Overview The University of British Columbia's Faculty of Medicine has appointed three world-renowned scientists as Eddie Goldenberg Research Chairs to accelerate breakthroughs in AI-driven protein design, drug deliver... -
A*STAR Successfully Identifies Bispecific Antibody Stability Risks: Enhancing Manufacturability and Robustness of Next-Gen Biologics
A*STAR Singapore Overview Researchers at A*STAR's Bioprocessing Technology Institute (BTI) in Singapore have successfully identified 'labile regions' within bispecific antibodies (BsAbs) that compromise their manufacturing and stability.... -
AI Accelerates Drug Discovery: AlphaFold, Generative Models Drive R&D Efficiency & Clinical Pipeline Growth
Markets Insider USA Overview AI has dramatically accelerated drug discovery over the past five years through advancements in protein structure prediction, generative chemistry, and phenotypic screening. Tools like DeepMind's AlphaFold ha... -
AI-Powered In Silico Design Revolutionizes RNA-LNP Therapies for Targeted Delivery and CRISPR Gene Editing
InSilicoMinds USA Overview In silico (computational) design is fundamentally transforming the development of lipid nanoparticle (LNP) and RNA therapeutics by enabling the precise optimization of LNP properties for tissue-specific drug de... -
Schrödinger Unveils ‘Bunsen’ AI Co-Scientist to Accelerate End-to-End Biologics Discovery Workflow with BioLuminate and LiveDesign Integration
Schrödinger USA Overview Schrödinger is hosting an event to demonstrate an integrated, end-to-end workflow accelerating biologics discovery and engineering through BioLuminate and LiveDesign. A highlight of this session is the introducti... -
AI Drug Discovery Faces New Pain Points: Chemical Models Deliver Results, While Biological Models Struggle to Cross the ‘Valley of Death’
Moomoo USA Overview In AI-driven drug discovery, chemical models have successfully accelerated R&D by efficiently identifying targets and generating novel molecular structures. However, advancements in biological models still need to... -
AI Biotechs Drive ‘Fail-Fast’ Drug Development in Biopharma, Powered by DeepMind’s AlphaFold
BioSpace USA Overview AI-centric biotechs like Isomorphic Labs and Generate Biomedicines are leveraging Google DeepMind's AlphaFold and proprietary 'dataverses' to propel a 'fail-fast' approach in drug discovery through in silico experim... -
Isomorphic Labs: AI-Designed Drugs Head to Human Trials, Reshaping Pharma’s Future
Wired USA Overview Isomorphic Labs, a Google DeepMind spin-off, is on the verge of commencing human clinical trials for drugs entirely designed by artificial intelligence. Leveraging its foundational AlphaFold system, the company aims to...
